Page last updated: 2024-10-26

diclofenac and Blood Clot

diclofenac has been researched along with Blood Clot in 19 studies

Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.

Research Excerpts

ExcerptRelevanceReference
"The study was performed to investigate, in an animal model of arterial thrombosis in vivo, whether diclofenac differentially influences platelet activation and thrombosis in vessels under non-stimulated conditions or during acute systemic inflammation, such as induced by tumor necrosis factor-alpha (TNF-alpha)."7.75Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. ( Buerkle, MA; Hellwig, N; Klauss, V; Krötz, F; Mannell, H; Pircher, J; Pohl, U; Sohn, HY; Struthmann, L, 2009)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."7.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
"Main parameter was thrombus weight."5.32Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004)
"We evaluated the relationship between baseline BP and change in BP on CV events (CVEs) in patients receiving NSAIDs or COX-2 inhibitors in the prospective randomized, double-blind, Multinational Etoricoxib and Diclofenac Arthritis Long-term Program (N = 34,701) comparing etoricoxib 60 or 90 mg or diclofenac 150 mg daily for a mean duration of 18 months."5.16Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. ( Brater, DC; Cannon, CP; Curtis, SP; Gammaitoni, A; Kaur, A; Krum, H; Laine, L; Peloso, PM; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2012)
" PP-g-(NIPAAm-r-APMA) films showed temperature-responsive swelling, smaller friction coefficients, hemolysis and thrombogenicity and higher cell compatibility, did not elicit secretion of cytokines, and took up remarkable amounts of diclofenac and ibuprofen and sustained delivery for several hours in phosphate buffer, pH 7."3.77Stimuli-responsive networks grafted onto polypropylene for the sustained delivery of NSAIDs. ( Alvarez-Lorenzo, C; Bucio, E; Concheiro, A; Contreras-García, A; Taboada, C, 2011)
"We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial."3.77Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011)
"The study was performed to investigate, in an animal model of arterial thrombosis in vivo, whether diclofenac differentially influences platelet activation and thrombosis in vessels under non-stimulated conditions or during acute systemic inflammation, such as induced by tumor necrosis factor-alpha (TNF-alpha)."3.75Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. ( Buerkle, MA; Hellwig, N; Klauss, V; Krötz, F; Mannell, H; Pircher, J; Pohl, U; Sohn, HY; Struthmann, L, 2009)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."3.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
"Pretreatment of rats by the cyclooxygenase inhibitors diclofenac, phenylbutazone, and aminophenazone did not influence kappa-carrageenin (KC) rat tail thrombosis (RTT) whereas pretreatment by aspirin, at high doses, and particularly sulfinpyrazone decreased RTT frequency, PGI2 or iloprost i."3.67Role of eicosanoids in the kappa-carrageenin rat tail thrombosis. ( Bekemeier, H; Hirschelmann, R, 1988)
" The cumulative gastrointestinal (GI)/liver adverse events (AEs) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort; HR (95% CI) of 0."2.74Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). ( Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C, 2009)
" The present prospective, placebo-controlled and double-blind study aimed to evaluate the analgesic efficacy of diclofenac, a non-steroid anti-inflammatory drug (NSAID), in combination with paracetamol and opioids."2.71Analgesic efficacy of diclofenac in combination with morphine and paracetamol after mastectomy and immediate breast reconstruction. ( Legeby, M; Olofsson, C; Sandelin, K; Wickman, M, 2005)
" Collagen and U46619 caused in vivo thrombus formation with the former, but not latter, sensitive to oral dosing with aspirin."1.37Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. ( Armstrong, PC; Emerson, M; Kirkby, NS; Mitchell, JA; Warner, TD; Zain, ZN, 2011)
"Main parameter was thrombus weight."1.32Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19903 (15.79)18.7374
1990's0 (0.00)18.2507
2000's9 (47.37)29.6817
2010's7 (36.84)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wise, J1
Nadesalingam, K1
Kirby, D1
Vollaard, EJ1
Kramers, C1
Brouwers, JR1
Combe, B1
Swergold, G2
McLay, J1
McCarthy, T1
Zerbini, C1
Emery, P1
Connors, L1
Kaur, A3
Curtis, S1
Laine, L3
Cannon, CP3
Struthmann, L1
Hellwig, N1
Pircher, J1
Sohn, HY1
Buerkle, MA1
Klauss, V1
Mannell, H1
Pohl, U1
Krötz, F1
Contreras-García, A1
Alvarez-Lorenzo, C1
Taboada, C1
Concheiro, A1
Bucio, E1
Ruff, CT1
Morrow, DA1
Jarolim, P1
Ren, F1
Contant, CF1
Curtis, SP3
Brune, K1
Armstrong, PC1
Kirkby, NS1
Zain, ZN1
Emerson, M1
Mitchell, JA1
Warner, TD1
Krum, H1
Gammaitoni, A1
Peloso, PM1
Smugar, SS1
Brater, DC1
Wang, H1
Weir, MR1
Umar, A1
Boisseau, M1
Yusup, A1
Upur, H1
Bégaud, B1
Moore, N1
Legeby, M1
Sandelin, K1
Wickman, M1
Olofsson, C1
Sibilia, J1
Deray, G2
Montalescot, G1
Valat, JP1
Héloire, F1
Ko, AT1
Bolognese, JA1
Cavanaugh, PF1
Reicin, AS2
Einecke, D1
Shapiro, D1
Sperling, RS1
Barr, E1
Yu, Q1
Bekemeier, H1
Hirschelmann, R1
Claros González, I1
Baños Gallardo, M1
Casal Alvarez, F1
Argüelles Toraño, M1
Campbell, WI1
Watters, CH1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445]Phase 323,498 participants (Actual)Interventional2003-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for diclofenac and Blood Clot

ArticleYear
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas

2006
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Current medical research and opinion, 2006, Volume: 22, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic;

2006

Trials

4 trials available for diclofenac and Blood Clot

ArticleYear
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:4

    Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergenci

2009
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
    Cardiovascular therapeutics, 2012, Volume: 30, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Body Weight; Comorbidity;

2012
Analgesic efficacy of diclofenac in combination with morphine and paracetamol after mastectomy and immediate breast reconstruction.
    Acta anaesthesiologica Scandinavica, 2005, Volume: 49, Issue:9

    Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents,

2005
Venous sequelae following i.v. administration of diclofenac.
    British journal of anaesthesia, 1989, Volume: 62, Issue:5

    Topics: Adult; Arm; Diclofenac; Female; Hand; Humans; Injections, Intravenous; Male; Thrombosis; Veins

1989

Other Studies

12 other studies available for diclofenac and Blood Clot

ArticleYear
Diclofenac shouldn't be prescribed to people with heart problems, drug agency says.
    BMJ (Clinical research ed.), 2013, Jul-02, Volume: 347

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Diclofenac; Drug and Narcotic Control; H

2013
Cardiovascular safety of non-steroidal anti-inflammatory drugs.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2013, Volume: 63, Issue:617

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebrovascular Disorders; Contraindications; Diclofenac; D

2013
[Interaction between NSAIDs and acetylsalicylic acid disregarded].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Inte

2014
Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:10

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arterioles; Cells, C

2009
Stimuli-responsive networks grafted onto polypropylene for the sustained delivery of NSAIDs.
    Acta biomaterialia, 2011, Volume: 7, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Diclofenac; Hemolysis; Humans; Ibuprofe

2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
    The Journal of rheumatology, 2011, Volume: 38, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein

2011
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.
    PloS one, 2011, Volume: 6, Issue:5

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Collagen; Cycl

2011
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:5

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy

2004
[Coronary risks with NSAID and coxibs. The end of hysteria].
    MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause

2006
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T

2002
Role of eicosanoids in the kappa-carrageenin rat tail thrombosis.
    Biomedica biochimica acta, 1988, Volume: 47, Issue:10-11

    Topics: Aminopyrine; Animals; Aspirin; Benzydamine; Cardiovascular Agents; Carrageenan; Diclofenac; Epoprost

1988
[Systemic thrombotic microangiopathy secondary to diclofenac].
    Medicina clinica, 1989, Mar-18, Volume: 92, Issue:10

    Topics: Diclofenac; Disseminated Intravascular Coagulation; Humans; Male; Microcirculation; Middle Aged; Thr

1989